Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia

Gäebel, Wolfgang; Riesbeck, Mathias; Wölwer, Wolfgang; Klimke, A.; Eickhoff, Matthias; Wilmsdorff, Martina von; Jockers-Scherübl, Maria C.; Kühn, Kai‐Uwe; Lemke, Matthias R.; Bechdolf, Andreas; Bender, Stefan; Degner, Detlef; Schlößer, R.; Schmidt, Lutz; Schmitt, Andrea; Jäger, Markus; Buchkremer, G; Falkai, Peter; Klingberg, Stefan; Köpcke, Wolfgang; Maier, Wolfgang; Häfner, Heinz; Ohmann, Christian; Salize, Hans Joachim; Schneider, Frank; Möller, Hans‐Jürgen

doi:10.4088/jcp.v68n1116

Cited by 76 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concomitant medications were permitted throughout the trial, except for additional antipsychotics or mood stabilizers. The results of the clinical study have been published recently [7]. Patients were diagnosed with schizophrenia according to DSM-IV by experienced clinical psychiatrists using a standardized clinical interview (SCID; German Version) [24].…”

Section: Methodsmentioning

confidence: 99%

Internal capsule size associated with outcome in first-episode schizophrenia

Wobrock

Gruber

Schneider‐Axmann

et al. 2009

Eur Arch Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

Subtle structural brain abnormalities are an established finding in first-episode psychosis. Nevertheless their relationship to the clinical course of schizophrenia is controversially discussed. In a multicentre study 45 first-episode schizophrenia patients (FE-SZ) underwent standardized MRI scanning and were followed up to 1 year. In 32 FE-SZ volumetric measurement of three regions of interests (ROIs) potentially associated with disease course, hippocampus, lateral ventricle and the anterior limb of the internal capsule (ALIC) could be performed. The subgroups of FE-SZ with good (12 patients) and poor outcome (11 patients), defined by a clinically relevant change of the PANSS score, were compared with regard to these volumetric measures. Multivariate analysis of covariance revealed a significant reduced maximal cross sectional area of the left ALIC in FE-SZ with clinically relevant deterioration compared to those with stable psychopathology. There were no differences in the other selected ROIs between the two subgroups. In conclusion, reduced maximal area of ALIC, which can be interpreted as a disturbance of fronto-thalamic connectivity, is associated with poor outcome during the 1 year course of first-episode schizophrenia.

show abstract

Section: Methodsmentioning

confidence: 99%

Internal capsule size associated with outcome in first-episode schizophrenia

Wobrock

Gruber

Schneider‐Axmann

et al. 2009

Eur Arch Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

show abstract

“…The group of schizophrenia inpatients included 18 unmedicated patients (US) and 17 medicated patients (MS), both with a first exacerbation of schizophrenia according to DSM-IV criteria. The medicated schizophrenia patients had been randomly and double-blind assigned to either haloperidol (mean dose±SD: 4.6±1.6 mg, range: 3-8 mg) or risperidone (4.5±2.4 mg, range: 2-10 mg) maintenance treatment, as part of a separate clinical trial, results of which are published elsewhere (41). US were never systematically treated with antipsychotics before and none of them took an antidepressant for at least four weeks.…”

Section: Participantsmentioning

confidence: 99%

Impaired Sensorimotor Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia

Quednow

Frommann

Berning

et al. 2008

Biological Psychiatry

131

View full text Add to dashboard Cite

show abstract

“…Data accrual is injectable risperidone, which has been shown to ongoing and results are being reported as they acbe efficacious in short-and long-term clinical crue. trials, [22][23][24][25][26] including those in patients unsatisfactorily treated with oral or depot conventional antipsy-…”

Section: Background and Objectivementioning

confidence: 99%

Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia

Olivares

Rodriguez-Martinez

Burón³

et al. 2008

Applied Health Economics and Health Policy

View full text Add to dashboard Cite

Treatment with long-acting injectable risperidone compared with previous antipsychotic medications resulted in a higher number of patients not requiring hospitalization, not relapsing, and not requiring hospitalization and not showing relapse, resulting in risperidone being more cost effective per month per patient.It is important to note that real-world variations in adherence would automatically be controlled from within a randomized control trial, and hence, any evaluation of variations in adherence inevitably requires a real-world focus. On the basis of these findings, which were obtained in real-world clinical practice, long-acting injectable risperidone is predicted to be the dominant strategy because it results in effective symptom control and direct medical cost savings. However, because of limitations in methodology, any conclusions should, at this stage, be treated as tentative, and confirmation in more detailed follow-up studies is required. Cost-effectiveness comparisons based on experimental evaluations of relapse minimization strategies are also required. In order to avoid estimation biases in the future, a prospectively designed study is needed.

show abstract

Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia

Cited by 76 publications

References 0 publications

Internal capsule size associated with outcome in first-episode schizophrenia

Internal capsule size associated with outcome in first-episode schizophrenia

Impaired Sensorimotor Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia

Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia

Contact Info

Product

Resources

About